慢性乙型肝炎患者使用替诺福韦长期抑制性治疗后接种佩格 -

StephenW

J Viral Hepat. 2017 Nov 1. doi: 10.1111/jvh.12820. [Epub ahead of print]
Unconventional T-cells in Chronic Hepatitis B Patients on Long-Term Suppressive Therapy with Tenofovir followed by a Peg-IFN Add-On Strategy: a randomized study.
Cannizzo ES1, Tincati C1, Binda F2, Ronzi P2, Cazzaniga FA1, Antinori S2, d'Arminio Monforte A1, Marchetti G1, Milazzo L2.
Author information

1
    Department of Health Sciences, Clinic of Infectious Diseases, ASST Santi Paolo e Carlo, University of Milan, Milan, 20142.
2
    Department of Clinical, Biomedical Sciences Luigi Sacco, III Division of Infectious Diseases University of Milan, Milan, 20157.

Abstract

HBV eradication in Chronic Hepatitis B (CHB) subjects is rarely achieved with either nucleos(t)ide analogues (NA) or pegylated interferon (Peg-IFN), which both have a limited effect in restoring immune responses. 30 CHB subjects on long-term treatment with tenofovir (TDF) and HBV suppression were enrolled and randomized 1:2 to either receive Peg-IFN-α-2a add-on therapy or continue TDF alone. We studied γδT and iNKT frequency and function (by flow cytometry) at baseline, at 12 weeks and 12 weeks after the end of treatment. A higher reduction of qHBsAg occurred in the Add-On compared with the NA group at W12 (p=0.016) and at W24 (p=0.012). A decline of qHBsAg > 0.5 log10 at week 24 occurred in 4/10 patients in the Add-On and 1/20 in the NA arm, respectively (p=0.03). HBsAg loss was seen in 20% of subjects in the Add-On and in none of the NA group. Compared to HBV negative, CHB on TDF showed lower frequency of iNKT (p=0.03) and γδT cells (p=0.03) as well as fewer γδT cells expressing Vδ2 T cell receptors (p=0.005). No changes in unconventional T cell frequency and function were shown in both Add-On and NA patients nor were differences detected between the two treatment groups. We report persistent impairment of unconventional T cells in CHB. Despite a greater qHBsAg decline in Add-On patients, our data failed to detect any effect of Peg-IFN treatment on unconventional T cells. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

HBV ; invariant Natural Killer T cell (iNKT; nucleos(t)ide analogues (NA; pegylated interferon (Peg-IFN; γδT cell

PMID:
    29091327
DOI:
    10.1111/jvh.12820

StephenW

J病毒肝脏。 2017年11月1日doi：10.1111 / jvh.12820。 [电子版提前打印]
慢性乙型肝炎患者使用替诺福韦长期抑制性治疗后接种佩格 - 干扰素加入策略的非常规T细胞：一项随机研究。
Cannizzo ES1，Tincati C1，Binda F2，Ronzi P2，Cazzaniga FA1，Antinori S2，d'Arminio Monforte A1，Marchetti G1，Milazzo L2。
作者信息

1
    米兰大学健康科学系，传染病临床科学系，桑特·保罗·卡洛，米兰，20142。
2
    生物医学临床科学系Luigi Sacco，米兰米兰大学传染病研究所III，2015年。

抽象

在核苷（酸）类似物（NA）或聚乙二醇化干扰素（Peg-IFN）的情况下，在慢性乙型肝炎（CHB）受试者中的HBV根除很少实现，其在恢复免疫应答方面具有有限的效果。 30名慢性乙型肝炎患者用替诺福韦（TDF）和HBV抑制进行长期治疗，并按1：2的比例随机接受Peg-IFN-α-2a加用治疗或单独继续使用TDF。我们在治疗结束后12周和12周时，在基线，γδT和iNKT频率和功能（通过流式细胞仪）研究了γδT和iNKT的频率和功能。与W12组（p = 0.016）和W24组（p = 0.012）相比，附加组中发生的qHBsAg降低更多。第24周qHBsAg下降> 0.5 log10分别发生在4/10位附加组和1/20位于NA组（p = 0.03）。 20％的受试者在附加组和NA组都没有发现HBsAg消失。与HBV阴性相比，TDF上的CHB显示iNKT（p = 0.03）和γδT细胞（p = 0.03）的频率较低，以及表达Vδ2T细胞受体的γδT细胞（p = 0.005）较少。在附加治疗和NA患者中均未显示非常规T细胞频率和功能的变化，也没有检测到两个治疗组之间的差异。我们报告CHB中非常规T细胞的持续损伤。尽管附加患者qHBsAg下降较多，但我们的数据未能检测到Peg-IFN治疗对非常规T细胞的任何影响。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

HBV;不变的天然杀伤T细胞（iNKT;核苷酸（t））类似物（NA;聚乙二醇化干扰素（Peg-IFN;γδT细胞

结论：
    29091327
DOI：
    10.1111 / jvh.12820